Expanded Access to Upadacitinib

ConditionsCrohn Disease Ulcerative Colitis Idiopathic Arthritis (Including sJIA, pJIA, or JPsA)Atopic Dermatitis Rheumatoid Arthritis Psoriatic Arthritis Axial Spondyloarthritis Non-radiographic Axial Spondyloarthritis Giant Cell Arteritis Systemic Lupus Erythematosus Alopecia Areata Non Segmental Vitiligo Hidradenitis Suppurativa

Trial statusAvailable

Trial phaseNot listed

Trial typeExpanded Access

Biological sexAll

AgeNot listed

SponsorAbbVie

About this trial

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to upadacitinib prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Eligibility criteria

Qualifiers

None

Disqualifiers

There are other suitable treatment options.

The participant qualifies for ongoing clinical trials.

Trial design

Treatments tested in this trial

Upadacitinib

Treatment groups

No treatment groups listed

Locations

This trial has no locations

Sponsors and collaborators

AbbVie

Lead sponsor

Source ClinicalTrials.gov